FindTrial
Sign In

Comprehensive Pituitary Function Assessments in COVID-19 Survivors

Comprehensive Pituitary Function Assessments in COVID-19 Survivors

Status
Unknown
Phases
Unknown
Study type
Observational
Source
TCTR
Registry ID
TCTR20230208007
Enrollment
50
Registered
2023-02-08
Start date
2022-10-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypopituitarism Hypopituitarism

Interventions

Follow-up of post-COVID-19 patients,Follow-up of post-COVID-19 patients
Diagnostic,Diagnostic
PostCOVID, mild to moderate severity,PostCOVID, severe to critical severity

Sponsors

Endocrine Society of Thailand
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Age >18

Exclusion criteria

Exclusion criteria: Preexisting hypopituitarism or endocrine dysfunction

Design outcomes

Primary

MeasureTime frame
Hypopituitarism 1, 3 month Baseline pituitary hormone testing, Glucagon stimulation test—

Secondary

MeasureTime frame
Presence of long COVID-19 syndrome 1, 3 months Symptoms and Piper fatigue scale—

Countries

Thailand

Contacts

Public ContactKrittin Ousirimaneechai

King Chulalongkorn Memorial Hospital

k.ous@Live.com0222564000

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026